Using two different methods (ssGSEA applied to NanoString IO 360 gene sets and MCP counter) to study immune populations, we observed highly significant differences in the immune infiltrate profiles of the post-NACT residual tumors between patients who experienced metastatic recurrence and those who did not.
← all excerpts
An immunological signature to predict outcome in patients with triple-negative breast cancer with residual disease after neoadjuvant chemotherapy.
1
—
—